Impact of aripiprazole discontinuation in remitted major depressive disorder: a randomized placebo-controlled trial

ConclusionsDefinitive conclusions could not be drawn owing to the small sample size. This study represents a starting point for investigating the safety of aripiprazole discontinuation on recurrence in patients with MDD who have achieved remission with AATA. Future studies with appropriate sample sizes calculated based on this study are needed.

http://link.springer.com/10.1007/s00213-024-06581-1

Source: Psychopharmacology - March 28, 2024 Category: Psychiatry Source Type: research